MPD: Measures involving fluoxetine

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Wiltshire2:1	Wiltshire2	tail suspension test	fluoxetine	TST duration of immobility [%] TST 38001 control fluoxetine	inbred	30	m	9-10wks	N=10	2011

Wiltshire2:3	Wiltshire2	open field test	fluoxetine	OFT center avoidance, thigmotaxis, 10 min test [%] OFT_thig 38003 control fluoxetine	inbred	30	m	10-11wks	N=11	2011

Wiltshire2:5	Wiltshire2	open field test	fluoxetine	OFT distance traveled, 10 min test [cm] OFT_dist 38005 control fluoxetine	inbred	30	m	10-11wks	N=11	2011

Wiltshire2:7	Wiltshire2	drug and metabolite quantification	fluoxetine	drug and metabolite concentration [ng/mL] fluoxetine 38007 fluoxetine norfluoxetine	inbred	30	m	10-11wks	N=11	2011

Wiltshire3:1	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:4	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:7	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:10	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:13	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:16	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:19	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:22	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAD1 (GAD67), relative fluorescence intensity GAD1 38122 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:25	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAL, relative fluorescence intensity GAL 38125 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:28	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:31	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:34	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:37	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GLO1, relative fluorescence intensity GLO1 38137 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:40	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GNB1, relative fluorescence intensity GNB1 38140 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:43	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GRIN1 (NMDA1), relative fluorescence intensity GRIN1 38143 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:46	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSK3B, relative fluorescence intensity GSK3B 38146 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:49	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:52	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex HDAC5, relative fluorescence intensity HDAC5 38152 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:55	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:58	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NPY, relative fluorescence intensity NPY 38158 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:61	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:64	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:67	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PPP1R1B, relative fluorescence intensity PPP1R1B 38167 control fluoxetine	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:70	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:73	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex S100B, relative fluorescence intensity S100B 38173 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:76	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:79	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:82	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:85	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:88	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:91	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire2

tail suspension test

fluoxetine

TST duration of immobility [%] TST 38001 control fluoxetine

inbred

30

m

9-10wks

N=10

2011

Wiltshire2

open field test

fluoxetine

OFT center avoidance, thigmotaxis, 10 min test [%] OFT_thig 38003 control fluoxetine

inbred

30

m

10-11wks

N=11

2011

Wiltshire2

open field test

fluoxetine

OFT distance traveled, 10 min test [cm] OFT_dist 38005 control fluoxetine

inbred

30

m

10-11wks

N=11

2011

Wiltshire2

drug and metabolite quantification

fluoxetine

drug and metabolite concentration [ng/mL] fluoxetine 38007 fluoxetine norfluoxetine

inbred

30

m

10-11wks

N=11

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GAD1 (GAD67), relative fluorescence intensity GAD1 38122 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GAL, relative fluorescence intensity GAL 38125 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GLO1, relative fluorescence intensity GLO1 38137 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GNB1, relative fluorescence intensity GNB1 38140 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GRIN1 (NMDA1), relative fluorescence intensity GRIN1 38143 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GSK3B, relative fluorescence intensity GSK3B 38146 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex HDAC5, relative fluorescence intensity HDAC5 38152 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex NPY, relative fluorescence intensity NPY 38158 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex PPP1R1B, relative fluorescence intensity PPP1R1B 38167 control fluoxetine

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex S100B, relative fluorescence intensity S100B 38173 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Filter Table Results